Skip to main content
SpringerLink
Log in

Human liver microsomal metabolism of paclitaxel and drug interactions

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The aim of this study was to investigate the influence of several anticancer drugs and investigational multidrug resistance (MDR) reversing agents on the hepatic metabolism of paclitaxel (Taxol) to its primary metabolites, 6 α-hydroxypaclitaxel (metabolite, MA) and 3′-p-hydroxypaclitaxel (metabolite, MB). There is significant inter-individual variability associated with the levels of these two metabolites. In many cases, 6α-hydroxypaclitaxel has been observed to be the predominant metabolite, in others, 3′-p-hydroxypaclitaxel has been the principal metabolite. The formation of 6α-hydroxypaclitaxel and 3′-p-hydroxypaclitaxel is catalyzed by cytochrome P450 isozymes CYP2C8 and CYP3A4, respectively. A number of factors, including co-administration of drugs and adjuvants, are known to influence the activity of these isozymes. Therefore, the influence of MDR reversing agents, R-verapamil, cyclosporin A (CsA) and tamoxifen and anti-cancer drugs doxorubicin, etoposide (VP-16) and cisplatin on paclitaxel metabolism was assessed employing human liver microsomes in vitro. Paclitaxel (10 μM) was incubated with human liver microsomes (1 mg protein, −0.34 nmol CYP) in the presence of a NADPH generating system at 37°C for 1 h, with and without the presence of interacting drug. Controls included incubations with quercetin and ketoconazole, known inhibitors of 6α-hydroxypaclitaxel and 3′-p-hydroxypaclitaxel formation, respectively. At the end of the incubation period, paclitaxel and the metabolites were extracted in ethyl acetate and analyzed employing an HPLC method. Significant inhibition of paclitaxel conversion to 6α-hydroxypaclitaxel and 3′-p-hydroxypaclitaxel was observed in the presence of R-verapamil, tamoxifen and VP-16 (P 0.005). Doxorubicin significantly inhibited the formation of 3′-p-hydroxypaclitaxel and CsA inhibited the formation of 6α-hydroxypaclitaxel (P 0.005). This study demonstrates that co-administration of several of the above listed compounds could lead to significant changes in the pharmacokinetics of paclitaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Schiff P.B., Fant J., Horwitz S. (1979): Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665–667.

    Article  CAS  PubMed  Google Scholar 

  2. Rowinsky E.K., Gilbert M.R., McGuire W.P. et al. (1991): Sequences of taxol and cisplatin: a phase I and pharmacologic studies. J. Clin. Oncol., 9, 1692–1703.

    CAS  PubMed  Google Scholar 

  3. Sledge G.W., Robert N., Sparano J.A. et al. (1994): Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin. Oncol., 21 (suppl. 8), 15–18.

    PubMed  Google Scholar 

  4. Hortobagyi G.N. (1997): Paclitaxel-based combination chemotherapy for breast cancer. Oncology, XX, 29–37.

    Google Scholar 

  5. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J.M.T., Vierira I., Wright M. (1994): Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 54, 386–392.

    CAS  PubMed  Google Scholar 

  6. Kumar G.N., Walle U.K., Walle T. (1994): Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J. Pharmacol. Exp. Ther., 268, 1160–1165.

    CAS  PubMed  Google Scholar 

  7. Harris J.W., Rahman A., Kim B-R., Guengerich F.P., Collins J.M. (1994): Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54, 4026–4035.

    CAS  PubMed  Google Scholar 

  8. Rahman A., Korekwa K.R., Grogan J., Gonzalez F.J., Harris J.W. (1994): Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54, 5543–5546.

    CAS  PubMed  Google Scholar 

  9. Walle T., Walle U.W., Kumar G.N., Bhalla K.N. (1995): Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos., 23, 506–512.

    CAS  PubMed  Google Scholar 

  10. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. (1995): Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 275, 566–575.

    CAS  PubMed  Google Scholar 

  11. Sonnichsen D.S., Hurwitz C.A., Pratt C.B., Shuster J.J., Relling M.V. (1994): Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J. Clin. Oncol. 12, 532–538.

    CAS  PubMed  Google Scholar 

  12. Beijnen J.H., Huizing M.T., ten Bokkel W.W. et al. (1994): Bioanalysis, pharmacokinetics and pharmacodynamics of the novel anti-cancer drug paclitaxel (Taxol). Semin. Oncol., 21 (suppl 8), 53–62.

    CAS  PubMed  Google Scholar 

  13. Berg S.L., Tolcher A., O’Shaughnessy J.A. et al. (1995): Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol., 13, 2039–2042.

    CAS  PubMed  Google Scholar 

  14. Huizing M.T., Sparreboom A., Rosing H., van Tellingen O., Pinedo H.M., Beijnen J.H. (1995): Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B: Biomed Appl., 674, 261–268.

    Article  CAS  Google Scholar 

  15. Kumar G., Ray S., Walle T. et al. (1995): Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6α-hydroxypaclitaxel. Cancer Chemother. Pharmacol., 36, 129–135.

    Article  CAS  PubMed  Google Scholar 

  16. Juranka P.F., Zastawny R.I., Ling V. (1989): P-glycoprotein: multidrug resistance and a superfamily of membrane-associated transport proteins. FASEB J., 3: 2583–2592.

    CAS  PubMed  Google Scholar 

  17. Horwitz S.B., Lothstein L., Manfredi J.J. et al. (1986): Taxol: Mechanisms of action and resistance. Ann. N.Y. Acad. Sci., 466, 733–744.

    Article  CAS  PubMed  Google Scholar 

  18. Lum B.L., Fisher G.A., Brophy N.A. et al. (1993): Clinical trials of modulators of multidrug resistance: pharmacokinetic and pharmacodynamic consideration. Cancer, 72, 3502–3514.

    Article  CAS  PubMed  Google Scholar 

  19. Stuart N.S.A., Philip, P., Harris A.L. et al. (1992): High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br. J. Cancer, 66, 833–839.

    CAS  PubMed  Google Scholar 

  20. Buckley M.M-T., Goa K.L., Tamoxifen. (1989): A re-appraisal of its pharmacodynamics and pharmacokinetic properties, and therapeutic use. Drugs, 37, 451–490.

    Article  CAS  PubMed  Google Scholar 

  21. Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. (1996): Metabolism of docetaxel by human cytochrome P450: interactions with paclitaxel and other anti-neoplastic agents. Cancer Res., 56, 58–65.

    CAS  PubMed  Google Scholar 

  22. Lum B.L., Kaubisch S., Yahanda A.M. et al. (1992): Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J. Clin. Oncol., 10, 1635–1642.

    CAS  PubMed  Google Scholar 

  23. Mani C., Gelboin H.V., Park S.S., Pearce R., Parkinson A., Kupfe D. (1993): Metabolism of the antimammary cancer anti-estrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21, 645–656.

    CAS  PubMed  Google Scholar 

  24. Kroemer H.K., Gautier J.C., Beaune P., Henderson C., Wolf C.R., Eichelbaum M. (1993): Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol., 348, 332–337.

    Article  CAS  PubMed  Google Scholar 

  25. Lemoine A., Azoulay D., Gries J.M. et al. (1993): Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation, 56, 1410–1414.

    Article  CAS  PubMed  Google Scholar 

  26. Leblanc G.A., Sundseth S.S., Weber G.F., Waxman D.J. (1992): Platinum anti-cancer drugs modulate P450 mRNA levels and differentially alter hepatic drug and steroid metabolism in male and female rats. Cancer Res., 52, 540–547.

    CAS  PubMed  Google Scholar 

  27. Relling M.V., Nemec J., Schuetz, E.G., Schuetz J.D., Gonzalez F.J., Korzekwa K.R. (1994): O-demethylation of epidophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol., 45, 352–358.

    CAS  PubMed  Google Scholar 

  28. Kivisko K.T., Kroemer H.K., Eichelbaum M. (1995): The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implication for drug interactions. Br. J. Clin. Pharmacol., 40, 523–530.

    Google Scholar 

  29. Lien E.A., Solheim E., Ueland P.M. (1991): Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51, 4837–4844.

    CAS  PubMed  Google Scholar 

  30. Hamann S.R., Todd G.R., McAllister R.G. (1983): The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology, 27, 1–8.

    Article  CAS  PubMed  Google Scholar 

  31. Lesser G.J., Grossman S.A., Eller S., Rowinsky E.K. (1995): The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother. Pharmacol., 37, 173–178.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Y -W. Zhu

    Present address: Division of Pharmaceutical Evaluation, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA

Authors and Affiliations

  1. Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati Medical Center, 3223 Eden Avenue, 45267-0004, Cincinnati, OH, USA

    P. B. Desai, J. Z. Duan & Y -W. Zhu

  2. Division of Basic Pharmaceutical Sciences, School of Pharmacy, Northeast Louisiana University, Monroe, Louisiana, USA

    S. Kouzi

Authors
  1. P. B. Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Z. Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y -W. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Kouzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desai, P.B., Duan, J.Z., Zhu, Y.W. et al. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur. J. Drug Metab. Pharmacokinet. 23, 417–424 (1998). https://doi.org/10.1007/BF03192303

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03192303

Keywords

Search

Navigation